Targets › DGAT2
1 program from 1 company in 1 trial: 1 Phase 3; Immunology; next expected readout Aug 2027.
Essential acyltransferase that catalyzes the terminal and only committed step in triacylglycerol synthesis by using diacylglycerol and fatty acyl CoA as substrates. Required for synthesis and storage of intracellular triglycerides. (UniProt, Q96PD7)
Open in Phaseline: the race on DGAT2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Sagimet Biosciences | Denifanstat DGAT2 inhibitor | DGAT2 | Phase 3 | Acne Vulgaris | Aug 2027 |
Acne Vulgaris (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.